Targeting ferroptosis to overcome drug resistance in lung cancer. [PDF]
Sheng P +7 more
europepmc +1 more source
Prevalence and factors associated with HIV drug resistance among adult persons living with HIV/AIDS in nine countries of Sub-Saharan Africa using population-based HIV impact assessments: 2015–2019 [PDF]
Edson Nsonga +3 more
openalex +1 more source
Predictive value of exosomes and their cargo in drug response/resistance of breast cancer patients
Heidi Schwarzenbach, Peter B. Gahan
openalex +2 more sources
Evaluating Shared Laboratory Services: Detecting Mycobacterium Tuberculosis Complex and Drug Resistance Using Molecular and Culture-Based Methods [PDF]
Julie Tans-Kersten +3 more
openalex +1 more source
Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley +1 more source
Identification of Specific LncRNA Markers in Severe Tuberculosis for Early Diagnosis
Siyu Yao,1,* Xiuxiu Ji,2,* Ruize Wang,1 Liping Pan,2 Qiuyue Liu1 1Department of Critical Care Medicine, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, People’s ...
Yao S, Ji X, Wang R, Pan L, Liu Q
doaj
Outsmarting Nightmare: Drug Resistance in <i>Acinetobacter baumannii</i>. [PDF]
Praveen A +4 more
europepmc +1 more source
Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon +4 more
wiley +1 more source

